Exchange Traded Concepts LLC Acquires 8,012 Shares of Bio-Rad Laboratories, Inc. $BIO

Exchange Traded Concepts LLC boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 37.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,592 shares of the medical research company’s stock after buying an additional 8,012 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Bio-Rad Laboratories were worth $8,966,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Farther Finance Advisors LLC boosted its stake in shares of Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after acquiring an additional 36 shares during the period. UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 24.0% during the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock worth $58,000 after acquiring an additional 40 shares during the last quarter. OneDigital Investment Advisors LLC raised its stake in Bio-Rad Laboratories by 1.9% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 2,954 shares of the medical research company’s stock valued at $828,000 after acquiring an additional 55 shares during the period. M&T Bank Corp lifted its holdings in Bio-Rad Laboratories by 3.7% during the 2nd quarter. M&T Bank Corp now owns 1,855 shares of the medical research company’s stock valued at $447,000 after purchasing an additional 66 shares during the last quarter. Finally, RK Asset Management LLC lifted its holdings in Bio-Rad Laboratories by 0.5% during the 4th quarter. RK Asset Management LLC now owns 14,573 shares of the medical research company’s stock valued at $4,415,000 after purchasing an additional 71 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 0.1%

Shares of NYSE:BIO opened at $265.16 on Monday. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $343.12. The business has a 50 day moving average of $281.43 and a 200-day moving average of $298.69. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. The stock has a market cap of $7.16 billion, a PE ratio of 9.50 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). The firm had revenue of $693.20 million for the quarter, compared to the consensus estimate of $694.64 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.Bio-Rad Laboratories’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter last year, the business posted $2.90 EPS. As a group, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analysts Set New Price Targets

BIO has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.